News & Updates

Cefmetazole and cefoxitin prove to be effective in the treatment of patients with urinary tract infections (UTIs) due to extended-spectrum beta-lactamase (ESBL)–producing Escherichia coli, according to two separate studies presented at IDWeek 2022.

While rare, infection with antibiotic-resistant gram-negative bacteria (AR-GNB) following a positive COVID-19 diagnosis is more severe and often results in worse outcomes, according to a study presented at the recent Virtual ID Week 2022.

In a real-world, territory-wide, propensity score (PS)–matched study during Hong Kong’s Omicron BA.2.2 wave, early initiation of molnupiravir or nirmatrelvir/ritonavir is shown to reduce the risks of mortality and in-hospital outcomes among community-dwelling outpatients with COVID-19. However, the risk of hospitalization is lowered with nirmatrelvir/ritonavir but not molnupiravir.

Adults with a high baseline HIV-1 RNA or low CD4 count may benefit from initial treatment with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), which has been shown to be safe and efficacious over 5 years of follow-up in a study presented at the ID Week 2022 Virtual Conference.

In patients with Clostridioides difficile infections (CDI), treatment with ridinilazole (RDZ) leads to high and sustained rates of clinical response, according to a study presented at the recently concluded Virtual ID Week 2022. Compared with vancomycin (VAN), RDZ also more strongly prevents recurrent CDI (rCDI).

Use of molnupiravir or nirmatrelvir/ritonavir in high-risk patients with mild-to-moderate COVID-19 is associated with reduced in-hospital mortality, reduced hospital admissions or readmissions, and potential healthcare cost savings, according to a real-world retrospective cohort study led by researchers from the Chinese University of Hong Kong and the University of Hong Kong.

Hospitals with higher staffing see lower rates of mortality among COVID-19 inpatients, a recent study has found.

COVID-19 patients with chronic statin exposure appear to be at lower risk of developing acute kidney injury (AKI) during hospitalization in addition to having reduced levels of inflammation, as reported in a study.